News & Events

Vivoryon Therapeutics N.V. new Home Member State

HALLE (SAALE) / MUNICH, Germany, 16 December 2020 – as a consequence of the conversion into an N.V., a public company under the laws of the Netherlands […]

Successful Relocation of Vivoryon Shares Package

HALLE (SAALE) / MUNICH, GERMANY, 14 December 2020 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; ISIN DE0007921835) has been informed by Hauck & Aufhäuser Privatbankiers AG […]

Vivoryon Therapeutics AG Announces Conversion into Vivoryon Therapeutics N.V.

HALLE (SAALE) / MUNICH, Germany, 30 November 2020 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) announced today that it has completed its conversion into an N.V., a […]

Vivoryon Therapeutics Reports Third Quarter 2020

HALLE (SAALE) / MUNICH, Germany, 26 November 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY; ISIN DE0007921835) announced today its third quarter business update for the period […]

Vivoryon Therapeutics AG to Publish its Third Quarter 2020 Business Update on November 26, 2020

HALLE (SAALE) / MUNICH, Germany, 19 November 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), a biotechnology company focused on developing first-in-class therapeutics targeting post-translational modifying […]

Ordinary General Meeting of Shareholders of Vivoryon Therapeutics AG

All proposed resolutions approved with large majority   HALLE (SAALE) / MUNICH, Germany, 01 October 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) announced today […]

Vivoryon Therapeutics Announces Notice of its Ordinary General Meeting of Shareholders to be Held on September 30, 2020

HALLE (SAALE) / MUNICH, GERMANY, 3 September 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) invites all shareholders to Vivoryon Therapeutics´ ordinary general meeting of […]

Vivoryon Therapeutics AG plans conversion into Naamloze Vennootschap (N.V.) under Dutch law

Vivoryon Therapeutics intends the transfer of the statutory seat to Amsterdam, the Netherlands, leading to a conversion into a public company under the laws of the […]

Vivoryon Therapeutics AG Reports Financial Results for H1 2020 and Provides Corporate Update

Conference call and webcast in English at 3:00 pm CEST / 09:00 am EDT Vivoryon and Nordic Bioscience collaboration Meprin protease inhibitors development program   HALLE (SAALE) / […]